Estudi dels mecanismes responsables de la Retinopatia Diabètica i desenvolupament de noves aproximacions de teràpia gènica

  • Bosch Tubert, Maria Fatima (Principal Investigator)
  • Anguela Martínez, Xavier (Scholar)
  • Jimenez Cenzano, Verónica (Scholar)
  • Barrero Victorio, Jennifer (Investigator)
  • Haurigot Mendoça, Virginia (Investigator)
  • Mann , Christopher John (Investigator)
  • Molas Laplana, Maria (Investigator)
  • Tafuro , Sabrina (Investigator)
  • Villacampa Alcubierre, Pilar (Scholar)

Project Details


Diabetes mellitus is the most common metabolic disease in humans. Chronic hyperglycemia is associated with the development of vascular alterations that lead to diabetic retinopathy. As a consequence of the microvascular pathology, diabetes is now the leading cause of adult blindness. Current treatments are invasive and offer temporary solutions. The design of more effective therapies requieres not only of the understanding of the mechanisms that lead to the development of the disease, but also of animal models in which to assay the new therapeutic approaches. Recently, we have observed that mice that overexpress IGF-I in the retina develop dibetic-like eye disease and therefore constitute an ideal animal model in which to study the disease ans assay new therapies. Thus, the first objective of this project is to complete the study of the molecular mechanisms underlying the development of diabetic retinopathy in our animal model. To this end, gene expression in different phases of retinopathy will be analyzed by microarray tecnology and the contribution of bone marrow stem cells to the retinopathy-associated vascular and neuronal alterations will be studied. In addiation, this project aims at developing new gene therapy approaches for diabetic retinopathy. Two different approaches will be tested: a)
Effective start/end date18/10/0630/12/09


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.